TC Biopharm (Holdings) Management

Management criteria checks 1/4

TC Biopharm (Holdings)'s CEO is Bryan Kobel, appointed in Jun 2021, has a tenure of 2.92 years. directly owns 0.003% of the company’s shares, worth $150.32. The average tenure of the management team and the board of directors is 2.6 years and 2 years respectively.

Key information

Bryan Kobel

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.9yrs
CEO ownership	0.003%
Management average tenure	2.6yrs
Board average tenure	2yrs

Recent management updates

Recent updates

CEO

Bryan Kobel (44 yo)

2.9yrs

Tenure

Mr. Bryan L. Kobel serves as Chief Executive Officer at TC Biopharm Limited. Mr. Kobel serves as Chief Executive Officer of TC Biopharm (Holdings) Plc since June 2021 and is its Director. He joined TC BioP...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bryan Kobel	CEO & Director	2.9yrs	no data	0.0033% £ 150.3
Martin Thorp	CFO & Director	5.2yrs	no data	0.000030% £ 1.4
Christopher Camarra	Executive Vice President of Communications	2.3yrs	no data	no data
Lauren Bor	Head of Commercial Development Division	less than a year	no data	no data

2.6yrs

Average Tenure

Experienced Management: TCBP's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Bryan Kobel	CEO & Director	no data	no data	0.0033% £ 150.3
Martin Thorp	CFO & Director	8.2yrs	no data	0.000030% £ 1.4
Arlene Morris	Non-Executive Independent Chair	2.3yrs	no data	no data
Mark Bonyhadi	Chairman of Scientific Advisory Board & Non-Executive Independent Director	2.3yrs	no data	no data
Edward Niemczyk	Non-Executive Independent Director	2.3yrs	no data	no data
Isabelle Riviere	Member of Scientific Advisory Board	1.6yrs	no data	no data
James Culverwell	Non-Executive Independent Director	2.3yrs	no data	no data
Daniel Olive	Member of Scientific Advisory Board	1.6yrs	no data	no data
Uma Lakshmipathy	Member of Scientific Advisory Board	2yrs	no data	no data
Erin Adams	Member of Scientific Advisory Board	2yrs	no data	no data
Blythe Sather	Member of Scientific Advisory Board	1.6yrs	no data	no data
Chris Bond	Member of Scientific Advisory Board	1.6yrs	no data	no data

2.0yrs

Average Tenure

68yo

Average Age

Experienced Board: TCBP's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

TC Biopharm (Holdings) Management

Management criteria checks 1/4

Key information

Recent management updates

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

High number of new and inexperienced directors

Recent updates

New major risk - Revenue size

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million.

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

New major risk - Share price stability

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC Biopharm (Holdings) Plc Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

First half 2022 earnings released: EPS: UK£0.93 (vs UK£6.78 loss in 1H 2021)

TC Biopharm (Holdings) Plc announced that it has received $7.35 million in funding

TC Biopharm (Holdings) Plc announced that it expects to receive $7.35 million in funding

Tc BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, Omnimmune(R), in Patients with Acute Myeloid Leukemia

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 14, 2022

TC Biopharm (Holdings) Plc Announces Additions to Scientific Advisory Board

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 01, 2022

TC Biopharm (Holdings) PLC Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $4 million.

TC Biopharm Announces Formation of Scientific Advisory Board

TC Biopharm (Holdings) Plc Receives CryoTC Trademark for Proprietary Cell Freezing Process

High number of new directors

TC Biopharm (Holdings) Plc Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

TC Biopharm (Holdings) Plc Announces Appointment of New Board Members

TC Biopharm (Holdings) Plc has completed an IPO in the amount of $17.54118 million.

No independent directors

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age